FY2030 Earnings Estimate for JSPR Issued By HC Wainwright

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Jasper Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.75) per share for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.47.

Other analysts also recently issued reports about the company. UBS Group started coverage on Jasper Therapeutics in a research report on Monday, March 23rd. They issued a “neutral” rating for the company. Rodman & Renshaw assumed coverage on shares of Jasper Therapeutics in a research note on Tuesday, January 13th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $19.88.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $0.88 on Wednesday. The company has a market cap of $24.52 million, a P/E ratio of -0.19 and a beta of 3.08. The business’s 50 day moving average price is $1.32 and its 200-day moving average price is $1.76. Jasper Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $7.19.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JSPR. Goldman Sachs Group Inc. boosted its holdings in Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after acquiring an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC purchased a new stake in Jasper Therapeutics in the third quarter worth $3,291,000. Velan Capital Investment Management LP increased its stake in Jasper Therapeutics by 86.1% in the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after purchasing an additional 1,234,567 shares during the period. Woodline Partners LP bought a new stake in shares of Jasper Therapeutics during the third quarter worth $2,475,000. Finally, Propel Bio Management LLC bought a new stake in shares of Jasper Therapeutics during the third quarter worth $2,449,000. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.